Suppr超能文献

利用急慢性疼痛、焦虑、共济失调和僵住症的啮齿动物模型,对大麻素受体2激动剂GW405833进行药理学和药代动力学特征研究。

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

作者信息

Valenzano Kenneth J, Tafesse Laykea, Lee Gary, Harrison James E, Boulet Jamie M, Gottshall Susan L, Mark Lilly, Pearson Michelle S, Miller Wendy, Shan Shen, Rabadi Leyana, Rotshteyn Yakov, Chaffer Suzanne M, Turchin Paul I, Elsemore David A, Toth Mathew, Koetzner Lee, Whiteside Garth T

机构信息

Department of Pharmacology, Purdue Pharma Discovery Research, Cranbury, NJ 08512, USA.

出版信息

Neuropharmacology. 2005 Apr;48(5):658-72. doi: 10.1016/j.neuropharm.2004.12.008.

Abstract

To date, two cannabinoid receptors have been identified, CB1 and CB2. Activation of these receptors with non-selective cannabinoid receptor agonists reduces pain sensitivity in animals and humans. However, activation of CB1 receptors is also associated with central side effects, including ataxia and catalepsy. More recently, a role for selective CB2 agonists in pain modification has been demonstrated. GW405833, a selective CB2 agonist, was recently reported to partially reverse the inflammation and hyperalgesia in a rat model of acute inflammation. In the current report, we extend the characterization and therapeutic potential of this compound. For the first time, we show that GW405833 selectively binds both rat and human CB2 receptors with high affinity, where it acts as a partial agonist (approximately 50% reduction of forskolin-mediated cAMP production compared to the full cannabinoid agonist, CP55,940). We also report for the first time that intraperitoneal administration of GW405833 (0.3-100 mg/kg) to rats shows linear, dose-dependent increases in plasma levels and substantial penetration into the central nervous system. In addition, GW405833 (up to 30 mg/kg) elicits potent and efficacious antihyperalgesic effects in rodent models of neuropathic, incisional and chronic inflammatory pain, the first description of this compound in these models. In contrast, analgesia, sedation and catalepsy were not observed in this dose range, but were apparent at 100 mg/kg. Additionally, GW405833 was not antihyperalgesic against chronic inflammatory pain in CB2 knockout mice. These data support the tenet that selective CB2 receptor agonists have the potential to treat pain without eliciting the centrally-mediated side effects associated with non-selective cannabinoid agonists, and highlight the utility of GW405833 for the investigation of CB2 physiology.

摘要

迄今为止,已鉴定出两种大麻素受体,即CB1和CB2。用非选择性大麻素受体激动剂激活这些受体可降低动物和人类的疼痛敏感性。然而,CB1受体的激活也与中枢副作用有关,包括共济失调和僵住症。最近,已证明选择性CB2激动剂在疼痛调节中发挥作用。GW405833是一种选择性CB2激动剂,最近有报道称它能部分逆转急性炎症大鼠模型中的炎症和痛觉过敏。在本报告中,我们扩展了该化合物的特性和治疗潜力。我们首次表明,GW405833以高亲和力选择性结合大鼠和人类CB2受体,在该受体上它作为部分激动剂发挥作用(与全大麻素激动剂CP55,940相比,可使福斯可林介导的环磷酸腺苷生成减少约50%)。我们还首次报告,给大鼠腹腔注射GW405833(0.3 - 100 mg/kg)后,血浆水平呈线性、剂量依赖性升高,并且能大量渗透进入中枢神经系统。此外,GW405833(高达30 mg/kg)在神经性、切口性和慢性炎症性疼痛的啮齿动物模型中引发强效且有效的抗痛觉过敏作用,这是该化合物在这些模型中的首次描述。相比之下,在这个剂量范围内未观察到镇痛、镇静和僵住症,但在100 mg/kg时明显出现。此外,GW405833对CB2基因敲除小鼠的慢性炎症性疼痛没有抗痛觉过敏作用。这些数据支持了这样一个原则,即选择性CB2受体激动剂有潜力治疗疼痛而不引发与非选择性大麻素激动剂相关的中枢介导的副作用,并突出了GW405833在研究CB2生理学方面的效用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验